# Addressing Fatigue, Sleep, and Cognitive Functioning As Part of Survivorship Care

# Paul Jacobsen, PhD

Healthcare Delivery Research Program

Division of Cancer Control and Population Sciences



# **Scope of the Problem**

# Cancer-related symptom burden is substantial

- 27% of off-therapy patients have > 3 moderate to severe symptoms<sup>1</sup>
- Most common symptoms: fatigue (27%) and disturbed sleep (22%)<sup>1</sup>

#### Poorly controlled symptoms contribute to:

- Poor quality of life including impaired physical and social functioning<sup>2</sup>
- Nonadherence with and discontinuation of oral therapies<sup>3,4</sup>
- Lower rates of return to work and impaired ability to work<sup>5,6</sup>

# Presentation of Fatigue, Sleep Problems, and Cognitive Problems in People with Cancer

- Pre-existing symptom
- Disease symptom
   Initial disease symptom
   Symptom of advancing disease
- Treatment side effect
- Persistent symptom after treatment completion
- New symptom after treatment completion

# **Assessment of Post-treatment Fatigue**

- Patient-reported outcome measures (e.g., BFI)<sup>1</sup>
- Case definition interview<sup>2</sup>

<sup>&</sup>lt;sup>1</sup>Mendoza et al, Cancer 1999;85:1186-96

<sup>&</sup>lt;sup>2</sup>Donovan et al, Psycho-Oncol 2013;22:737-44

# **Risk Factors for Post-treatment Fatigue**

- Pre-treatment fatigue<sup>1</sup>
- Type of cancer treatment<sup>2</sup>
- Body mass index<sup>3</sup>
- Polymorphisms in inflammation-related genes<sup>4</sup>

IL1B

IL6

**TNFA** 

<sup>&</sup>lt;sup>1</sup>Goedendorp et al, J Pain Symptom Manage 2013;45:213-22


<sup>&</sup>lt;sup>2</sup>Donovan et al, J Pain Symptom Manage 2004;28:373-80

<sup>&</sup>lt;sup>3</sup>Andrykowski et al, Cancer 2010;116:5740-48

<sup>&</sup>lt;sup>4</sup>Bower, Nat Rev Clin Oncol 2014;11:597-609

# **Mechanisms for Post-treatment Fatigue**

- Persisting inflammation (IL-1RA, CRP)<sup>1</sup>
- Cognitive and behavioral responses<sup>2</sup>



<sup>&</sup>lt;sup>1</sup>Bower et al Brain Behave Immun 2013;30:S48-57 <sup>2</sup>Donovan et al, Health Psychol; 2007;26:464-72

# **Intervention Effects - Fatigue**

- Meta-analysis of 113 RCTs<sup>1</sup>
- 11,525 patients (78% female)
- 45 studies of patients who completed treatment

Variable <sup>a</sup>	Overall WES (95% CI)	P Value	No. of Effect Sizes
After primary: exercise	0.26 (0.18 to 0.34)	<.001	29
After primary: psychological	0.42 (0.29 to 0.55)	<.001	13
After primary: exercise and psychological	0.32 (0.17 to 0.47)	<.001	7
After primary: pharmaceutical	0.08 (-0.17 to 0.32)	.55	4

<sup>&</sup>lt;sup>1</sup>Mustian et al, JAMA Oncol, 2017;3:961-8

# Interventions for Post-treatment Fatigue: ASCO<sup>1</sup> and Pan-Canadian Guidelines<sup>2</sup>

#### Recommended

- Exercise
- Cognitive-behavioral therapy
- Psychoeducation

#### **Limited Evidence**

- Mindfulness-based approaches
- Yoga
- Acupuncture

#### No Evidence

Psychostimulant medications

<sup>&</sup>lt;sup>1</sup>Bower et al, J Clin Oncol 2014;32:1840-50

<sup>&</sup>lt;sup>2</sup>www.capo.ca/pdf/CRF\_Guideline.pdf

# **Future Directions: Fatigue**

#### **Risk Factors and Mechanisms**

- Expand findings on genetic risk factors
- Clarify underlying biological mechanisms

#### **Treatment**

- Identify recommended intensity of exercise
- Adapt effective interventions for more widespread dissemination and implementation
- Explore new intervention strategies

# **Assessment of Post-treatment Sleep Problems**

- Patient-reported outcome measures (e.g., PSQI)<sup>1</sup>
- Polysomnography
- Actigraphy






<sup>&</sup>lt;sup>1</sup>Buysse et al, Psychiatry Res 1989;28:193-213

# **Risk Factors for Post-treatment Sleep Problems**

- Pre-treatment sleep problems<sup>1</sup>
- Type of cancer treatment<sup>1</sup>
- Arousability<sup>2</sup>

# **Mechanism for Post-treatment Sleep Problems**


Cognitive and behavioral responses<sup>1</sup>



<sup>&</sup>lt;sup>1</sup>Savard et al, J Clin Oncol 2009:27:5233-5239

# Intervention Effects - Sleep Problems

- Meta-analysis of 8 RCTs of cognitive-behavioral therapy for insomnia (CBT-I)<sup>1</sup>
- 752 patients (5 studies of breast cancer patients)



<sup>&</sup>lt;sup>1</sup>Johnson et al, Sleep Med Rev 2016;27:20-8

# Interventions for Post-treatment Insomnia: NCCN<sup>1</sup> and Pan-Canadian Guidelines<sup>2</sup>

#### Recommended

- Sleep hygiene measures
- Cognitive-behavioral therapy
- Hypnotic medications (short-term/intermittent)
- Psychoeducation

### **Suggested**

Exercise

# **Future Directions: Sleep Problems**

#### **Assessment**

Investigate apnea and other sleep disorders

#### **Risk Factors and Mechanisms**

- Identify agents interfering with sleep
- Clarify underlying biological mechanisms

#### **Treatment**

- Adapt effective interventions for more widespread dissemination and implementation
- Consider implications of symptom cluster concept

# **Post-treatment Cognitive Problems**

#### The New York Times

#### Health

## Chemotherapy Fog Is No Longer Ignored as Illusion



Sally Ryan for The New York Times

Debbie Kamplain of Peoria, III., hired a personal organizer to help her prepare to move her family to Indiana.

By JANE GROSS

Published: April 29, 2007

# **Assessment of Post-treatment Cognitive Problems**

- Patient-reported outcome measures (e.g., FACT-Cog¹)
- Neuropsychological tests Core measures<sup>2</sup>

Domains	Measures
Learning and memory	Hopkins Verbal Learning Test-Revised
Processing speed	Trail Making Test, Controlled Oral Word Association
Executive function	Trail Making Test Controlled Oral Word Association

- Functional imaging studies (fMRI, fPET)<sup>3</sup>
- Quantitative electroencephalography (qEEG)<sup>4</sup>

# **Risk Factors for Post-treatment Cognitive Problems**

- Age<sup>1</sup>
- Cognitive reserve<sup>1</sup>
- Genetic polymorphisms
  - APOE<sup>2</sup>
  - COMT<sup>3</sup>

<sup>&</sup>lt;sup>1</sup>Ahles et al, J Clin Oncol 2010; 28:4434-40

<sup>&</sup>lt;sup>2</sup>Ahles et al, Psycho-Oncol 2003;12;612-19

<sup>&</sup>lt;sup>3</sup>Small et al, Cancer 2011;117:1369-76

# **Mechanisms for Post-treatment Cognitive Problems**

#### Direct neurotoxic effects<sup>1,2,3</sup>

- Volume loss
- Reduced white matter integrity
- Altered neurochemistry and metabolism

Cytokine deregulation<sup>1,2,3</sup>

Hormonal changes<sup>1</sup>

<sup>&</sup>lt;sup>1</sup>Janelsins et al, Intl Rev Psychiatry 2014;26:102-13

<sup>&</sup>lt;sup>2</sup>Joly et al, J Pain Symptom Manage 2015;50:843-41

<sup>&</sup>lt;sup>3</sup>Bray et al, Cancer Forum 2017;41:1

# Interventions for Post-treatment Cognitive Problems

- Cognitive training<sup>1</sup>
- Memory and attention adaptation training<sup>1</sup>
- Cognitive rehabilitation<sup>1</sup>
- EEG neurofeedback<sup>1</sup>
- Exercise, yoga, Tai Chi, Qigong<sup>2,3</sup>
- Psychostimulant medications<sup>3</sup>
- Acetylcholinesterase inhibitors<sup>3</sup>

# **Future Directions: Cognitive Problems**

#### **Assessment**

Integrate different assessment approaches

#### **Risk Factors and Mechanisms**

- Expand findings on genetic risk factors
- Clarify structural and functional brain changes

#### **Treatment**

- Conduct full-scale trials of promising interventions
- Explore possibility of preventing cognitive changes

# **Develop Evidence-based Treatment Guidelines**

# Moving Guideline Recommendations into Practice

#### Screening

#### **Assessment**

Focused history
In-depth evaluation of presenting symptoms
Identification of contributing factors

# **Management and Treatment**

Education, support, and self-management strategies
Psychological and psychosocial interventions
Pharmacologic Interventions



# **Barriers to More Effective Symptom Control**

#### Symptoms are not systematically assessed and reported

- Patient-reported outcomes (PROs) not used in many practice settings
- Even when collected, PRO data may not facilitate symptom control

#### Symptoms are not adequately managed

- Limited awareness of existing clinical practice guidelines
- Difficulty accessing resources for symptom management

#### Lack of systematic efforts to translate research into practice

- RCTs show benefits of integrated symptom assessment and reporting
- Implementation science approach yet to be applied

# Cancer Moonshot<sup>SM</sup> Blue Ribbon Panel Recommendation

# Strategic research investment, based on implementation science, to accelerate clinical adoption of integrated systems to:

- Gather and monitor patient-reported symptoms
- Provide decision support and care using evidence-based symptom management guidelines



#### **Conclusions**











- **T0** Fill gaps in understanding biological basis of common symptoms
- **T1** Develop new intervention strategies based on mechanistic understanding
- T2 Conduct full-scale trials of promising interventions
- **T3** Improve routine symptom management through implementation research
- **T4** Promote widespread use of PROs to be able to evaluate adequacy of symptom management at population level





# **Triage and Stepped Care Models**

